Corporate Banner
Satellite Banner
Medicinal Chemistry
Scientific Community
Become a Member | Sign in
Home>News>This Article

Malvern Publishes New Whitepaper that Explores AQbD

Published: Friday, May 16, 2014
Last Updated: Friday, May 16, 2014
Bookmark and Share
The whitepaper is freely available for download from

A new whitepaper on the application of Analytical Quality by Design (AQbD) to particle size assessment has been published by Malvern Instruments. AQbD is an innovative approach to the development and validation of analytical methods that brings the benefits of Quality by Design (QbD) to pharmaceutical analysis.

Malvern’s new whitepaper, ‘Beyond SOPs - Exploring the rigor and requirements of Analytical QbD’, introduces the AQbD concept, explains the associated workflow and illustrates how to apply AQbD when developing methods for laser diffraction particle sizing. The whitepaper is freely available for download from the Malvern resource center

QbD strategies are now firmly entrenched throughout pharmaceutical development and manufacture, and the benefits of their broader application are being recognized. AQbD is the application of QbD to analytical method development, which involves systematically identifying the risks associated with the variables that may impact analysis.

It calls for a more detailed understanding of the analytical method and the factors that can influence it, to establish a design space which offers the reward of robust analytical methods that improve throughout the lifecycle of pharmaceutical product.

The whitepaper introduces the regulatory benefits of applying AQbD approach to method development and highlights the parallels between AQbD and the more established QbD workflow. It goes on to present experimental results showing how to scope the method operable design region (MODR).

This is the range of operating parameters that ensures accurate analysis, for both wet and dry laser diffraction particle size analysis. It also covers method validation and the need to implement a carefully constructed control strategy to ensure consistently robust and precise analysis.

Malvern Instruments played a leading role in the introduction of SOP-driven particle size analysis more than a decade ago and delivers the know-how, technology and instrumentation to support continuing innovation in pharmaceutical analysis.

‘Beyond SOPs - Exploring the rigor and requirements of Analytical QbD’ concludes with a review of the tools and software features of the Mastersizer 3000 that can help with the implementation of AQbD to particle size measurement.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,600+ scientific posters on ePosters
  • More than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Scientific News
Atriva Therapeutics GmbH Develops Innovative Flu Drug
Highly effective against seasonal and pandemic influenza.
Study Removes Cancer Doubt for Multiple Sclerosis Drug
Researchers from Queen Mary University of London are calling on the medical community to reconsider developing a known drug to treat people with relapsing Multiple sclerosis after new evidence shows it does not increase the risk of cancer as previously thought.
New Hope for Personalized Treatment of Eczema
Pharmaceutical researchers at Oregon State University have developed a new approach to treat eczema and other inflammatory skin disorders that would use individual tests and advanced science to create personalized treatments based on each person's lipid deficiencies.
Inroads Against Leukaemia
Potential for halting disease in molecule isolated from sea sponges.
Researchers Disguise Drugs As Platelets to Target Cancer
Researchers have for the first time developed a technique that coats anticancer drugs in membranes made from a patient’s own platelets.
HIV Patients Should Be Included in Early Clinical Trials of Anti-TB Drugs
Tuberculosis is the number one cause of death in HIV-infected patients in Africa and a leading cause of death in this population worldwide.
Combination Drug Therapy Shrinks Pancreatic Tumors In Mice
Two drugs that affect the structure and function of DNA have been found to block the growth of pancreatic tumor cells in mice, researchers hope the drugs can soon be tested in humans with the disease.
Seeking A Better Way To Design Drugs
NIH funds research at Worcester Polytechnic Institute to advance a new chemical process for more effective drug development and manufacturing.
Old Drug Performs New Tricks
Cambridge-led research reveals the powers of a "wonder drug" that has lain under the noses of doctors for 50 years.
Diabetes Drugs May Actually Release Sugar Into the Blood
A family of drugs used to treat Type 2 diabetes could promote the release of sugars into the blood - something the drugs are supposed to prevent, Cambridge scientists have claimed.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,600+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos